Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

ICP Mass Spectrometer

By Drug Discovery Trends Editor | June 16, 2009

AgilentAgilent Technologies Inc. introduces the 7700 Series Inductively Coupled Plasma – Mass Spectrometer (ICP-MS) trace element analyzer. This successor to the world’s best-selling ICP-MS, the Agilent 7500 Series, provides unmatched data integrity, is simple to operate and occupies the smallest amount of bench space by far of any ICP-MS instrument. ICP-MS analysis is becoming more routine while labs are measuring greater numbers of elements, to lower levels, in more challenging samples.


The most obvious feature of the new 7700 Series is its small size, occupying just 73 cm of bench space. The mainframe footprint is more than 30 percent smaller than any other ICP-MS. Despite its small footprint, the 7700 Series sets a new standard for ICP-MS performance and ease-of-use in a rugged package.


Collision/reaction cells have been adopted as the industry-standard technology for removing spectral interferences in ICP-MS. Agilent’s Octopole Reaction System (ORS), featuring helium collision mode, provides the reliable and effective interference removal, especially for complex and unknown sample types. The 7700 Series features a new, third-generation cell (ORS3) that further improves the efficiency of helium mode, eliminating the need to use reaction mode (with reactive cell gases such as hydrogen) in almost all applications. This simplifies operation and eliminates false positives that frequently occur with reaction mode, thereby improving data quality. The new collision/reaction cell, plus Agilent’s unique High Matrix Introduction technology, which is standard on the 7700, make the instrument particularly well suited for complex sample types such as food, wastewater and soil digests. A redesigned ion lens improves sensitivity and reduces background noise across the mass range.


The 7700 Series features Agilent’s new ICP-MS MassHunter software, which is easy to learn and use while offering the power and flexibility needed by routine and research labs. MassHunter is Agilent’s common MS software platform, used across the entire family of Agilent GC/MS and LC/MS instruments, greatly simplifying staff training and support.


ICP-MS MassHunter incorporates many new productivity-enhancing features such as Expert Autotune, One Click Plasma Setting and Batch-at-a-Glance real-time data review. To meet the growing requirement for speciation measurement, the 7700 Series easily connects to Agilent’s 1200 Series liquid chromatography or 7890 Series gas chromatography systems. Now with MassHunter’s fully integrated chromatographic data analysis, speciation measurement by ICP-MS has become truly routine.


Agilent


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE